Sertoli-Leydig Cell Tumors: Hormonal Profile After Dynamic Test with GnRH Analogue Triptorelin Represents a Useful Tool to Evaluate Tumoral Hyperandrogenism

October 2014 in “ Gynecological Endocrinology ”

Jenni Turra, Marnie Granzotto, M Gallea, Diego Faggian, Lorena Conte, Pietro Litta, Roberto Vettor, Roberto Mioni

Sertoli-Leydig cell tumor hyperandrogenism testosterone GnRH analogue triptorelin ovarian steroids steroidogenesis virilization differential diagnosis PCOS SLCT GnRH

TLDR Triptorelin helps evaluate hormone production in Sertoli-Leydig cell tumors.

The document describes a case study of a 15-year-old female with a Sertoli-Leydig cell tumor (SLCT) causing hyperandrogenism. Elevated testosterone levels were observed, and a GnRH-analogue test with triptorelin showed an exaggerated secretion of ovarian steroids. The patient's hormonal levels were significantly higher compared to healthy women and similar to those of healthy men and PCOS patients. After tumor removal, her hormonal levels decreased, and virilization symptoms were reduced. The study suggests that the GnRH-analogue test is a useful tool for characterizing steroidogenesis in SLCT and may assist in differential diagnosis. It also indicates that SLCTs may respond to physiological stimuli like GnRH analogue, which could have therapeutic implications. The document highlights the importance of considering SLCT in the differential diagnosis of virilization symptoms in reproductive-age women. The number of participants in the study is not mentioned.

View this study on tandfonline.com →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

research Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred Because of Clinical Hyperandrogenism

352 citations, January 2006 in “The Journal of Clinical Endocrinology and Metabolism”

Most women referred for excess male hormone symptoms had polycystic ovary syndrome (PCOS), with other conditions being less common.

Similar Research

5 / 297 results

Menopausal Androgen Excess-Associated Cardio-Metabolic Risk: Clues for Ovarian Leydig Cell Tumor (Case Report and Mini-Review of Literature)

research Menopausal Androgen Excess-Associated Cardio-Metabolic Risk: Clues for Ovarian Leydig Cell Tumor (Case Report and Mini-Review of Literature)

5 citations, January 2017 in “Acta Endocrinologica”

High androgen levels in postmenopausal women may suggest an ovarian tumor, and removing it can improve heart and metabolic health.

research Approach to Androgen Excess in Women: Clinical and Biochemical Insights

14 citations, March 2022 in “Clinical Endocrinology”

The document concludes that a systematic approach is crucial to identify causes of androgen excess in women beyond the most common cause, Polycystic ovary syndrome (PCOS).

research Occult Ovarian Leydig Cell Tumor: When Laboratory Tells More Than Imaging

5 citations, October 2013 in “Endocrine”

Blood tests can detect ovarian Leydig cell tumors when scans don't, and surgery can confirm and treat these tumors.

research Androgen- and Estrogen-Secreting Adrenal Cancers

14 citations, December 2010 in “Seminars in Oncology”

Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.

research Ovarian Leydig Cell Tumor and Postmenopausal Hirsutism with Signs of Virilization

4 citations, March 2021 in “Case Reports”

A woman's excessive hair growth and masculine features were due to a rare benign ovarian tumor and endometrial cancer, which improved after surgery.